Durable remission of large B-cell lymphoma transformed from lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia successfully treated with sequential immunochemotherapy followed by reduced-intensity allogeneic stem cell transplantation.

摘要

Although most patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM) have an indolent clinical course with a median survival of 60 months, 5-13% of them experience transformation into diffuse, large B-cell lymphoma (DLBCL). The prognosis after large-cell transformation is very poor, with a reported median survival of 2-5 months, and no effective therapeutic approach has been established. Here, we report a case of transformed DLBCL from LPL/WM successfully treated with sequential rituximab-based immunochemotherapy immediately followed by reduced-intensity conditioned allogeneic stem cell transplantation (RICT).